ABC | Volume 112, Nº4, Abril 2019

Artigo de Revisão Ferrari et al Inibidores da PCSK9 na prática clínica Arq Bras Cardiol. 2019; 112(4):453-460 1. Schlatter RP , Hirakata VN, Polanczyk CA. Estimating the direct costs of ischemic heart disease: evidence from a teaching hospital in BRAZIL, a retrospective cohort study. BMC Cardiovasc Disord. 2017;17(1):180. 2. BallantyneCM.Low-density lipoproteinsandrisk forcoronaryarterydisease. Am J Cardiol. 1998;82(9A):3Q-12Q. 3. Chaudhary R, Mathew D , Bliden K, Tantry US, Sharma T, Gesheff MG, et al. Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. Curr Med Res Opin. 2017;33(11):1979-84. 4. Khera AV , Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18(6):331-44. 5. Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med. 2017; 167(11):ITC81-ITC96. 6. Sabatine MS. Advances in the treatment of dyslipidemia. Cleve Clin J Med. 2016;83(3):181-6. 7. Rodriguez F , Harrington RA. Cholesterol, cardiovascular risk, statins, PCSK9 inhibitors, and the future of LDL-C lowering. JAMA. 2016;316(19):1967-8. 8. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. 9. Landmesser U, Chapman MJ , Stock JK, Amarenco P , Belch JJF , Borén J, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39(14):1131-43. 10. Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune A Neto, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol. 2017;109(2Supl.1):1-76. 11. Chaudhary R, Garg J, ShahN, Sumner A. PCSK9 inhibitors: a newera of lipid lowering therapy. World J Cardiol. 2017;9(2):76-91. 12. Stein EA, Raal F . Reduction of low-density lipoprotein cholesterol by monoclonalantibody inhibitionofPCSK9. AnnuRevMed.2 014;65:417-31. 13. Schmidt AF , Pearce LS, Wilkins JT , Overington JP , Hingorani AD, Casas JP . PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Apr 28;4:CD011748. 14. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr , Kastelein JJ, et al. Rosuvastatin to prevent vascular events inmen andwomenwith elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. 15. Stossel TP . The discovery of statins. Cell. 2008;134(6):903-5. 16. American College of Cardiology. ODYSSEYOutcomes: Results Suggest Use of PCSK9 Inhibitor Reduces CV Events, LDL-C in ACS Patients [Internet]. Washington DC: American College of Cardiology; 2018. [citado 15 mar. 2018]. Disponível em: https://www.acc.org/latest-in-cardiology/ articles/2018/03/05/15/53/sat-9am-odyssey-outcomes-cv-outcomes-with- alirocumab-after-acs-acc-2018. 17. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. 18. Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation. 2018;138(8):756-766. 19. Nicholls SJ, Puri R, Anderson T, BallantyneCM, Cho L, Kastelein JJ, et al. Effect ofevolocumabeonprogressionofcoronarydisease instatin-treatedpatients: The GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373-84. 20. Kühnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, et al. Alirocumabe inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55(10):2103-12. 21. Choi J, Khan AM, JarminM, Goldenberg N, Glueck CJ, Wang P. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumabe and evolocumabe, a post-commercialization study. Lipids Health Dis. 2017;16(1):141. 22. Weintraub WS, Gidding SS. PCSK9 inhibitors: a technology worth paying for? Pharmacoeconomics. 2016;34(3):217-20. 23. Mayor S. NICE recommends PCSK9 inhibitors for patients not responding to statins. BMJ. 2016 May 8;353:i2609. 24. Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune A Neto, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose - 2017. Arq Bras Cardiol. 2017;109(2 Supl.1):1-76. 25. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314-29. 26. Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. ClinCardiol. 2017;40(4):243-54. 27. Landmesser U, John Chapman M, Farnier M, Gencer B, Gielen S, Hovingh GK, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/ kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38(29):2245-55. 28. Momtazi AA, BanachM, PirroM, Stein EA, Sahebkar A. PCSK9 and diabetes: is there a link? Drug Discov Today. 2017;22(6):883-95. 29. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537-43. 30. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High- dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010;51(9):2714-21. 31. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis. 2011 Feb 28;10:38. 32. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-42. 33. Roehrich ME, Mooser V , Lenain V , Herz J, Nimpf J, Azhar S, et al. Insulin- secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem. 2003;278(20):18368-75. 34. de Carvalho LSF , Campos AM, Sposito AC. Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care. 2018;41(2):364-67. 35. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP , Deedwania P , De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumabe in patients with and without diabetes and the effect of evolocumabe on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941-50. 36. Sahebkar A, Di Giosia P, Stamerra CA, Grassi D, Pedone C, Ferretti G, et al. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: ameta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol. 2016;81(6):1175-90. 37. Cao YX, Li S, Liu HH, Li JJ. Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2018;8(9):e022348. Referências 459